CRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Up 12.2% in December
CRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Up 12.2% in December
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) was the recipient of a large growth in short interest during the month of December. As of December 30th, there was short interest totalling 10,480,000 shares, a growth of 12.2% from the December 15th total of 9,340,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the short-interest ratio is presently 9.9 days. Approximately 14.0% of the shares of the company are short sold.
Insider Activity
In related news, CEO Samarth Kulkarni sold 25,000 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, October 26th. The stock was sold at an average price of $54.81, for a total value of $1,370,250.00. Following the completion of the sale, the chief executive officer now owns 290,279 shares of the company's stock, valued at approximately $15,910,191.99. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 75,000 shares of company stock valued at $3,744,250 in the last 90 days. Insiders own 5.30% of the company's stock.
Get CRISPR Therapeutics alerts:Hedge Funds Weigh In On CRISPR Therapeutics
Several large investors have recently made changes to their positions in CRSP. Allworth Financial LP increased its holdings in CRISPR Therapeutics by 21.0% in the second quarter. Allworth Financial LP now owns 737 shares of the company's stock valued at $45,000 after buying an additional 128 shares in the last quarter. Steward Partners Investment Advisory LLC increased its stake in shares of CRISPR Therapeutics by 8.2% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,944 shares of the company's stock valued at $118,000 after purchasing an additional 148 shares in the last quarter. HC Advisors LLC raised its holdings in CRISPR Therapeutics by 2.1% in the 2nd quarter. HC Advisors LLC now owns 7,432 shares of the company's stock worth $452,000 after purchasing an additional 154 shares during the period. Bouvel Investment Partners LLC boosted its position in CRISPR Therapeutics by 1.0% during the third quarter. Bouvel Investment Partners LLC now owns 18,726 shares of the company's stock worth $1,224,000 after purchasing an additional 190 shares in the last quarter. Finally, Cetera Investment Advisers grew its holdings in CRISPR Therapeutics by 3.0% in the second quarter. Cetera Investment Advisers now owns 8,064 shares of the company's stock valued at $490,000 after purchasing an additional 237 shares during the period. 71.51% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. Morgan Stanley started coverage on shares of CRISPR Therapeutics in a research note on Tuesday, October 11th. They set an "underweight" rating and a $37.00 price objective for the company. EF Hutton Acquisition Co. I assumed coverage on shares of CRISPR Therapeutics in a research note on Thursday, January 5th. They issued a "buy" rating and a $75.00 price target for the company. Royal Bank of Canada cut their target price on shares of CRISPR Therapeutics from $79.00 to $70.00 and set a "sector perform" rating for the company in a research report on Wednesday, November 2nd. JMP Securities dropped their target price on CRISPR Therapeutics from $100.00 to $70.00 and set a "market outperform" rating for the company in a research report on Thursday. Finally, Credit Suisse Group cut their price objective on shares of CRISPR Therapeutics from $90.00 to $78.00 in a research note on Wednesday, November 2nd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $98.22.CRISPR Therapeutics Trading Up 4.1 %
CRSP traded up $1.94 during midday trading on Friday, hitting $49.61. 899,061 shares of the company were exchanged, compared to its average volume of 996,654. The company's 50 day simple moving average is $49.65 and its 200 day simple moving average is $60.91. The firm has a market capitalization of $3.88 billion, a price-to-earnings ratio of -5.64 and a beta of 1.77. CRISPR Therapeutics has a 1-year low of $38.94 and a 1-year high of $86.95.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last issued its earnings results on Tuesday, November 1st. The company reported ($2.24) EPS for the quarter, topping analysts' consensus estimates of ($2.30) by $0.06. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $3.53 million. CRISPR Therapeutics had a negative return on equity of 31.34% and a negative net margin of 4,831.79%. On average, equities analysts anticipate that CRISPR Therapeutics will post -9.25 EPS for the current year.
CRISPR Therapeutics Company Profile
(Get Rating)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
See Also
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
CRISPR治療股份公司(納斯達克代碼:CRSP-GET評級)在12月份獲得了空頭股數的大幅增長。截至12月30日,空頭股數共有1048萬股,比12月15日的934萬股增長了12.2%。以日均成交量1,06萬股計算,目前短息比率為9.9天。該公司約14.0%的股份被賣空。
內幕活動
在相關新聞中,首席執行官Samarth Kulkarni在10月26日星期三的交易中出售了25,000股CRISPR治療公司的股票。這隻股票的平均售價為54.81美元,總價值為1,370,250.00美元。出售完成後,首席執行官現在擁有290,279股公司股票,價值約15,910,191.99美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可在以下網址獲得此超鏈接。在過去的90天裏,內部人士已經出售了75,000股公司股票,價值3,744,250美元。內部人士持有該公司5.30%的股份。
到達CRISPR治療公司警報:對衝基金對CRISPR治療公司的看法
幾家大型投資者最近改變了他們在CRSP的頭寸。Allworth Financial LP在第二季度增持了CRISPR Treateutics 21.0%的股份。Allworth Financial LP現在擁有該公司737股股票,價值4.5萬美元,上個季度又購買了128股。Steward Partners Investment Consulting LLC在第二季度將其在CRISPR Treateutics的股份增加了8.2%。Steward Partners Investment Consulting LLC現在擁有該公司1,944股股票,價值11.8萬美元,上個季度又購買了148股。HC Advisors LLC在第二季度將其在CRISPR Treateutics的持股增加了2.1%。HC Advisors LLC在此期間又購買了154股,現在擁有7,432股該公司股票,價值452,000美元。Bouvel Investment Partners LLC在第三季度將其在CRISPR治療公司的頭寸增加了1.0%。Bouvel Investment Partners LLC現在擁有18,726股該公司股票,價值1,224,000美元,上個季度又購買了190股。最後,Cetera Investment Advisers在第二季度將其在CRISPR治療公司的持股增加了3.0%。Eltera Investment Advisers在此期間又購買了237股,現在擁有8,064股該公司股票,價值49萬美元。71.51%的股票目前由機構投資者和對衝基金持有。
分析師升級和下調評級
幾位股票分析師最近對該股發表了評論。摩根士丹利在10月11日星期二的一份研究報告中開始對CRISPR治療公司的股票進行報道。他們為該公司設定了“減持”評級和37.00美元的目標價。EF Hutton Acquisition Co.我在1月5日星期四的一份研究報告中假設了CRISPR治療公司的股票。他們對該公司的評級為“買入”,目標價為75美元。11月2日,週三,加拿大皇家銀行在一份研究報告中將CRISPR治療公司的股票目標價從79.00美元下調至70.00美元,併為該公司設定了“行業表現”評級。JMP證券公司將CRISPR治療公司的目標價從100.00美元下調至70美元,並在週四的一份研究報告中為該公司設定了“市場表現優於大盤”的評級。最後,瑞士信貸集團在11月2日星期三的一份研究報告中將CRISPR治療公司的股票目標價從90.00美元下調至78.00美元。兩名投資分析師對該股的評級為賣出,六名分析師給出了持有評級,十名分析師對該公司給予了買入評級。根據MarketBeat的數據,CRISPR治療公司目前的共識評級為“持有”,共識目標價為98.22美元。CRISPR治療公司股價上漲4.1%
CRSP在週五午盤交易中上漲1.94美元,觸及49.61美元。該公司股票成交量為899,061股,而其平均成交量為996,654股。該公司的50日簡單移動均線切入位在49.65美元,200日簡單移動均線切入位在60.91美元。該公司的市值為38.8億美元,市盈率為-5.64倍,貝塔係數為1.77。CRISPR治療公司的一年低點為38.94美元,一年高位為86.95美元。
CRISPR Treateutics(納斯達克:CRSP-GET評級)最近一次發佈收益報告是在11月1日(星期二)。該公司公佈本季度每股收益(2.24美元),比分析師普遍預期的(2.30美元)高出0.06美元。該公司本季度營收為90萬美元,而市場普遍預期為353萬美元。CRISPR治療公司的淨資產回報率為負31.34%,淨利潤率為負4831.79%。平均而言,股票分析師預計CRISPR治療公司本年度的每股收益將達到9.25美元。
CRISPR治療公司簡介
(獲取評級)
CRISPR治療公司是一家基因編輯公司,專注於利用其專有的CRISPR/Cas9平臺開發治療嚴重疾病的變革性基因藥物。CRISPR/Cas9是一項革命性的基因編輯技術,允許對基因組DNA進行精確的、定向的改變。CRISPR Treateutics已經在廣泛的疾病領域建立了一系列治療計劃,包括血紅蛋白疾病、腫瘤學、再生醫學和罕見疾病。
另請參閲
- 免費獲取StockNews.com關於CRISPR治療的研究報告(CRSP)
- 市場回顧周-1/16-1/20
- Old Dominion是否表明Trucking正在踩剎車?
- 諾德斯特龍對零售業降價的擔憂
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓認為中國推動了23年的增長
接受CRISPR治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對CRISPR治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧